FDA approves drug to treat rel/ref MCL

Print Friendly, PDF & Email


Acalabrutinib (Calquence)
Photo from AstraZeneca
The US Food and Drug Administration (FDA) has granted accelerated approval to the BTK inhibitor acalabrutinib (Calquence, formerly ACP-196). The drug is now approved to treat adults with mantle cell lymphoma (MCL) who have received at least 1 prior therapy. The FDA’s accelerated approval pathway is used for... [Read Article]
Print Friendly, PDF & Email

EMA recommends orphan designation for G100 to treat FL

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
The European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products has recommended orphan designation for G100 for the treatment of follicular lymphoma (FL). G100 contains the synthetic small molecule toll-like receptor-4 agonist glucopyranosyl lipid A. G100 works by activating innate and adaptive immunity in the tumor microenvironment to generate... [Read Article]
Print Friendly, PDF & Email

Natural selection opportunities tied to cancer rates

Print Friendly, PDF & Email


Cancer patient receiving chemotherapy
Photo by Rhoda Baer
Countries with the lowest opportunities for natural selection have higher cancer rates than countries with the highest opportunities for natural selection, according to a study published in Evolutionary Applications. Researchers said this is because modern medicine is enabling people to survive cancers, and their genetic... [Read Article]
Print Friendly, PDF & Email